Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics, Inc. for investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave a false impression about the approval of its New Drug Application for Anaphylm, leading to a significant stock price drop after deficiencies were identified by the FDA. Investors who suffered losses have until May 4, 2026, to apply for lead plaintiff in the lawsuit.

Original reporting
Published Mar 31, 2026, 6:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline — source image
Decision brief

The 30-second read

$AQSTBearishHigh
01

Why it matters

Legal action and FDA deficiencies have created negative investor sentiment, impacting stock valuation.

02

Market read

Legal and regulatory issues are significant catalysts affecting AQST's stock, with potential ripple effects in the biotech sector.

03

What to watch

Potential pipeline advancements or upcoming catalysts not mentioned in the news could offset legal risks.

Timing: Immediate, as legal deadlines and investor actions are upcoming.

Background

The lawsuit alleges misrepresentation regarding FDA approval of a key drug, leading to a stock price drop.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

High relevance due to recent legal action and negative sentiment.

Expected impact

Potential further decline in stock price by 5-10% in the near term.

Evidence & confidence

Legal issues and FDA setbacks typically lead to investor pessimism and stock price drops, especially with a bearish sentiment score of -0.60.

Market effects

Potential negative impact on biotech and life sciences sectors due to legal and regulatory concerns.

Limited regional impact; primarily affects US-based biotech stocks.

Moderate, as FDA decisions influence global biotech investor sentiment.

Counterpoint

If the lawsuit leads to a settlement or positive legal outcome, AQST could recover, presenting a buying opportunity.

Key entities

  • Bragar Eagel & Squire, P.C.

    Legal firm initiating class action lawsuit against AQST.

  • Aquestive Therapeutics, Inc.

    Target of the lawsuit due to alleged false impressions about drug approval.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.